Kevzara OverviewSarilumab (trade name Kevzara) is a human monoclonal antibody against the interleukin-6 receptor. Regeneron and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and EMA approval on 23 June 2017. Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial. Contents 1 Clinical trials 1.1 Rheumatoid arthritis 2 History ...
Read more Kevzara Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sarilumab
Recent Kevzara Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 150mg/1.14ml, 200mg/1.14ml
NDC Database Records for Kevzara: (2 results)Sorted by National Drug Code
- 0024-5908 Kevzara 150 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
- 0024-5910 Kevzara 200 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC